|
Name |
oxalicine B
|
| Molecular Formula | C30H33NO7 | |
| IUPAC Name* |
NA
|
|
| SMILES |
CC1=CC[C@H]2[C@]([C@]13[C@H](C4=C(O3)C=C(OC4=O)C5=CN=CC=C5)O)(CC[C@]([C@]26CCC(=O)OC6)(C(=C)C)O)C
|
|
| InChI |
InChI=1S/C30H33NO7/c1-17(2)29(35)12-11-27(4)22(28(29)10-9-23(32)36-16-28)8-7-18(3)30(27)25(33)24-21(38-30)14-20(37-26(24)34)19-6-5-13-31-15-19/h5-7,13-15,22,25,33,35H,1,8-12,16H2,2-4H3/t22-,25-,27+,28-,29+,30+/m0/s1
|
|
| InChIKey |
GADSICAILMLRQB-GVRUMSNVSA-N
|
|
| Synonyms |
oxalicine B; CHEMBL474673; ZINC40915180; NCGC00380810-01!; (3R,2'R,5'S)-2'beta,3''beta-Dihydroxy-6''-(3-pyridyl)-2'-isopropenyl-4'aalpha,6'-dimethyl-3',4',4'a,8'abeta-tetrahydrodispiro[2H-pyran-3(4H),1'(2'H)-naphthalene-5'(8'H),2''(3''H)-[4H]furo[3,2-c]pyran]-6,4''(5H)-dione
|
|
| CAS | NA | |
| PubChem CID | 21593946 | |
| ChEMBL ID | CHEMBL474673 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 519.6 | ALogp: | 2.3 |
| HBD: | 2 | HBA: | 8 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 115.0 | Aromatic Rings: | 6 |
| Heavy Atoms: | 38 | QED Weighted: | 0.428 |
| Caco-2 Permeability: | -4.887 | MDCK Permeability: | 0.00002000 |
| Pgp-inhibitor: | 0.112 | Pgp-substrate: | 0.505 |
| Human Intestinal Absorption (HIA): | 0.079 | 20% Bioavailability (F20%): | 0.283 |
| 30% Bioavailability (F30%): | 0.919 |
| Blood-Brain-Barrier Penetration (BBB): | 0.868 | Plasma Protein Binding (PPB): | 76.02% |
| Volume Distribution (VD): | 1.507 | Fu: | 20.19% |
| CYP1A2-inhibitor: | 0.139 | CYP1A2-substrate: | 0.833 |
| CYP2C19-inhibitor: | 0.346 | CYP2C19-substrate: | 0.593 |
| CYP2C9-inhibitor: | 0.323 | CYP2C9-substrate: | 0.061 |
| CYP2D6-inhibitor: | 0.012 | CYP2D6-substrate: | 0.101 |
| CYP3A4-inhibitor: | 0.925 | CYP3A4-substrate: | 0.639 |
| Clearance (CL): | 5.927 | Half-life (T1/2): | 0.428 |
| hERG Blockers: | 0.587 | Human Hepatotoxicity (H-HT): | 0.787 |
| Drug-inuced Liver Injury (DILI): | 0.807 | AMES Toxicity: | 0.024 |
| Rat Oral Acute Toxicity: | 0.902 | Maximum Recommended Daily Dose: | 0.974 |
| Skin Sensitization: | 0.217 | Carcinogencity: | 0.581 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.011 |
| Respiratory Toxicity: | 0.929 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002410 | ![]() |
0.765 | D06CNP | ![]() |
0.286 | ||
| ENC003611 | ![]() |
0.669 | D02STN | ![]() |
0.284 | ||
| ENC002080 | ![]() |
0.641 | D04GJN | ![]() |
0.243 | ||
| ENC004976 | ![]() |
0.575 | D0V4WD | ![]() |
0.234 | ||
| ENC002102 | ![]() |
0.522 | D0Q4SD | ![]() |
0.226 | ||
| ENC002118 | ![]() |
0.500 | D0EP0C | ![]() |
0.222 | ||
| ENC003423 | ![]() |
0.500 | D02CNR | ![]() |
0.220 | ||
| ENC002412 | ![]() |
0.496 | D0I2SD | ![]() |
0.217 | ||
| ENC003422 | ![]() |
0.478 | D0IX6I | ![]() |
0.212 | ||
| ENC005020 | ![]() |
0.394 | D0IL7L | ![]() |
0.212 | ||